Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. (ATTAIN 267)

A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia or Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.

The study will enroll new subjects (hereafter referred as "de novo" subjects) with schizophrenia, or bipolar I disorder, manic or mixed episode with or without psychotic features, and rollover subjects with schizophrenia from 31-09-266 (hereafter referred to as "Study 266"). All de novo subjects must enter the screening period of the study. Subjects who are screened and are not required to go through Phase 1 will complete a Phase 2 baseline visit prior to their participation in Phase 2.

Study Design: Treatment, Single Group Assignment, Open Label, Active Control, Safety/Efficacy Study

Study Overview

• Status: Terminated
• Conditions: Adolescent Schizophrenia; Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
• Intervention / Treatment: Drug: Aripiprazole

• Study Type: Interventional
• Enrollment (Actual): 524
• Phase: Phase 3

Contacts and Locations

Study Locations

• Bulgaria
  • Bourgas, Bulgaria, 8000
    • Study Site
  • Pazardjik, Bulgaria, 4400
    • Study Site
  • Plovdiv, Bulgaria, 4000
    • Study Site
  • Rousse, Bulgaria, 7004
    • Study Site
  • Sofia, Bulgaria, 1431
    • Study Site 2
  • Targovishte, Bulgaria, 7700
    • Study Site
  • Varna, Bulgaria, 9010
    • Study Site 1
  • Varna, Bulgaria, 9010
    • Study Site 2
• Croatia
  • Rijeka, Croatia, 51000
    • Study Site
  • Zagreb, Croatia, 10000
    • Study Site 1
  • Zagreb, Croatia, 10000
    • Study Site 2
• Hungary
  • Budapest, Hungary, H-1021
    • Study Site
  • Budapest, Hungary, H-1135
    • Study Site
  • Gyula, Hungary, H-5700
    • Study Site
  • Szeged, Hungary, H-6725
    • Study Site
• India
  • Guntur, India, 522001
    • Study Site
  • Andhra Pradesh
    • Vijayawada, Andhra Pradesh, India, 520002
      • Study Site
    • Visakhapatnam, Andhra Pradesh, India, 530002
      • Study Site
    • Visakhapatnam, Andhra Pradesh, India, 530017
      • Study Site
  • Gujarat
    • Ahmedabad, Gujarat, India, 380006
      • Study Site 1
    • Ahmedabad, Gujarat, India, 380006
      • Study Site 2
    • Ahmedabad, Gujarat, India, 380013
      • Study Site
    • Maninagar, Ahmedabad, Gujarat, India, 380008
      • Study Site
  • Karnataka
    • Mangalore, Karnataka, India, 575001
      • Study Site
  • Kerala
    • Calicut, Kerala, India, 673009
      • Study Site
  • Maharashtra
    • Nasik, Maharashtra, India, 422101
      • Study Site
  • Punjab
    • Ludhiana, Punjab, India, 141001
      • Study Site
  • Rajasthan
    • Jaipur, Rajasthan, India, 302017
      • Study Site
  • Tamil Nadu
    • Chennai, Tamil Nadu, India, 600003
      • Study Site
    • Maduri, Tamil Nadu, India, 625020
      • Study Site
  • Uttar Pradesh
    • Kanpur, Uttar Pradesh, India, 208005
      • Study Site
    • Lucknow, Uttar Pradesh, India, 226003
      • Study Site
    • Varanasi, Uttar Pradesh, India, 221005
      • Study Site
• Malaysia
  • Wilayah Persekutuan
    • Kuala Lumpur, Wilayah Persekutuan, Malaysia, 50603
      • Study Site
• Philippines
  • Iloilo City, Philippines, 5000
    • Study Site
  • Mandaluyong City, Philippines, 1553
    • Study Site
  • Cavite
    • Dasmarinas City, Cavite, Philippines, 4114
      • Study Site
  • Metro Manila
    • Manila City, Metro Manila, Philippines, 1000
      • Study Site
• Poland
  • Białystok, Poland, 15-879
    • Study Site
  • Gdansk Wrzeszcz, Poland, 80-282
    • Study Site
  • Toruń, Poland, 87-100
    • Study Site
  • Wrocław, Poland, 50-227
    • Study Site
  • Wrocław, Poland, 54-235
    • Study Site
• Romania
  • Bucharest, Romania, 041914
    • Study Site
  • Craiova, Dolj, Romania, 200620
    • Study Site
  • Iasi, Romania, 700282
    • Study Site
  • Cluj
    • Cluj-Napoca, Cluj, Romania, 400084
      • Study Site
  • Timis
    • Timisoara, Timis, Romania, 300239
      • Study Site
• Russian Federation
  • Ekaterinburg, Russian Federation, 620030
    • Study Site
  • Kazan, Russian Federation, 420061
    • Study Site
  • Lipetsk, Russian Federation, 399313
    • Study Site
  • Moscow, Russian Federation, 124617
    • Study Site
  • Moscow, Russian Federation, 127083
    • Study Site
  • Nizhniy Novgorod, Russian Federation, 603155
    • Study Site
  • Novosibirsk, Russian Federation, 630091
    • Study Site
  • Orenburg region, Russian Federation, 460551
    • Study Site
  • Petrozavodsk, Russian Federation, 185001
    • Study Site
  • Saratov, Russian Federation, 410028
    • Study Site
  • St. Petersburg, Russian Federation, 190005
    • Study Site
  • St. Petersburg, Russian Federation, 197376
    • Study Site
  • Tomsk, Russian Federation, 634014
    • Study Site
  • Tonnelnyi Township, Russian Federation, 357034
    • Study Site
  • Yaroslavl, Russian Federation, 150003
    • Study Site
• Serbia
  • Belgrade, Serbia, 11000
    • Study Site 1
  • Belgrade, Serbia, 11000
    • Study Site 2
  • Novi Sad, Serbia, 21000
    • Study Site
• Taiwan
  • Taipei City, Taiwan, 110
    • Study Site
• Ukraine
  • Dnepropetrovsk, Ukraine, 49005
    • Study Site
  • Donetsk, Ukraine, 83037
    • Study Site
  • Kharkiv, Ukraine, 61068
    • Study Site 1
  • Kharkiv, Ukraine, 61068
    • Study Site 2
  • Kherson, Ukraine, 73488
    • Study Site
  • Lugansk, Ukraine, 91045
    • Study Site
  • Lviv, Ukraine, 79021
    • Study Site
  • Odessa, Ukraine, 65006
    • Study Site
  • Simferopol Crimea, Ukraine, 95006
    • Study Site
  • Temopil, Ukraine, 4620
    • Study Site
  • Vinnytsya, Ukraine, 21005
    • Study Site
• United States
  • Alabama
    • Dothan, Alabama, United States, 36303
      • Study Site
  • California
    • Downey, California, United States, 90241
      • Study Site
  • Florida
    • Miami, Florida, United States, 33155
      • Study Site
    • Miami, Florida, United States, 33166
      • Study Site
  • Georgia
    • Atlanta, Georgia, United States, 30308
      • Study Site
    • Smyrna, Georgia, United States, 30080
      • Study Site
  • Illinois
    • Oak Brook, Illinois, United States, 60523
      • Study Site
  • Kansas
    • Wichita, Kansas, United States, 67214
      • Study Site
  • Minnesota
    • Minneapolis, Minnesota, United States, 55454
      • Study Site
  • New York
    • Buffalo, New York, United States, 14215
      • Study Site
    • Stony Brook, New York, United States, 11794
      • Study Site
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27517
      • Study Site
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • Study Site
    • Cleveland, Ohio, United States, 44106
      • Study Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73116
      • Study Site
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19139
      • Study Site
  • Texas
    • Houston, Texas, United States, 77090
      • Study Site
    • San Antonio, Texas, United States, 78258
      • Study Site
    • The Woodlands, Texas, United States, 77381
      • Study Site
  • Virginia
    • Richmond, Virginia, United States, 23230
      • Study Site
  • Washington
    • Bellevue, Washington, United States, 98004
      • Study Site
    • Bothell, Washington, United States, 98011
      • Study Site
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53227
      • Study Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 17 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects 13-17 years old (Schizophrenia); Subjects 10-17 years old (Bipolar manic or mixed episode)* [*Bulgaria will enroll Schizophrenia subjects only.]
• Subjects with a current diagnosis of schizophrenia, and a history of the illness (diagnosis or symptoms) for at least 6 months prior to screening (as per subject, family, or healthcare provider, or by previous medical records).
• Subjects with a current diagnosis of bipolar I disorder, manic or mixed episode with or without psychotic features (diagnosis or symptoms) experiencing symptoms for at least 1 week prior to screening. * [*These subjects will not be eligible to enroll in Bulgaria]
• Subjects who have shown previous response to antipsychotic treatment (other than clozapine) and are not resistant to treatment with other antipsychotics.
• Subjects who are currently being treated with oral antipsychotics other than clozapine, and are not resistant to treatment with other antipsychotics.
• Inpatient or outpatient status, with the exception of acute hospitalization due to psychiatric reasons at the time of screening or before Phase 2.

Exclusion Criteria:

• All subjects: diagnosis of schizoaffective disorder, autism, pervasive developmental disorder (PDD), OCD, or PTSD.
• Subjects with schizophrenia: a current major depressive episode.
• Subjects with bipolar manic or mixed episode: presenting with a clinical picture and/or history that is consistent with a diagnosis of bipolar II disorder or bipolar disorder not otherwise specified.
• Subjects with delirium, dementia, amnesia or other cognitive disorders; subjects with psychotic symptoms that are better accounted for by another general medical condition(s) or direct effect of a substance (i.e., medication, illicit drug use, etc.).
• Subjects with any neurological disorder, with the exception of Tourette's syndrome.
• Subjects experiencing major depressive episode at the time of screening other than subjects diagnosed with bipolar I disorder mixed episode.
• Subjects who are currently receiving clozapine or have received clozapine at any time in the past are ineligible for entry into the study.
• Subjects who meet the DSM-IV-TR criteria for substance dependence (including alcohol and benzodiazepines, but excluding caffeine and nicotine) within the past 180 days prior to screening.
• Subjects who have epilepsy, a history of seizures (except for a single childhood febrile seizure or post-traumatic seizure), or a history of severe head trauma or stroke, or have a history or current evidence of other unstable medical conditions.
• Subjects with a history of subclinical hypothyroidism (TSH ≥ 4.0 mIU/L), known hypothyroidism, or hyperthyroidism (unless the condition has been stabilized with medications for at least 90 days prior to entry into Phase 1 or Phase 2).
• Subjects who have a medical history of uncontrolled diabetes, labile or unstable diabetes (brittle diabetes), newly diagnosed diabetes, or clinically significant abnormal blood glucose levels (defined as fasting blood glucose ≥ 125 mg/dL).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1 and Phase 2; Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)	Drug: Aripiprazole; Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Adverse Events (AEs)	An AE was defined as any untoward medical occurrence in a participant or participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. A treatment emergent adverse event (TEAE) was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study medication, whether or not considered to have a causal relationship with the study medication. A serious-AE or reaction was any untoward occurrence that, at any dose, was fatal, life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was any other medically significant event that, based on appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above.	Adverse events were recorded from the time of the informed consent was signed throughout the 24 month treatment period until the follow-up visit 30 (± 3) days after the end of trial.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Laboratory Values of Potential Clinical Relevance	The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.	Baseline to Month 24
Incidence of Physical Examination Findings of Potential Clinical Relevance	The physical examination evaluation was one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.	Baseline to Month 24
Incidence of Vital Signs of Potential Clinical Relevance	Vital signs are taken at Baseline, Weeks 1, 2, 3, 4, 6, 8, and Months 3, 4, 6, 9, 12, 15, 18, 21, 24 of Phase 2 (Visits beyond Month 12 only for de novo subjects). Assessments included orthostatic (supine and standing) blood pressure (BP), heart rate and body temperature. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Abnormal vital signs in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.	Baseline to Month 24
Mean Change From Baseline by Week in Abnormal Involuntary Movement Scale (AIMS)	The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.	Baseline to Month 24
Mean Change From Baseline by Week in Simpson-Angus Scale (SAS) Total Score	The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.	Baseline to Month 24
Mean Change From Baseline by Week in Barnes Akathisia Rating Scale (BARS) Score	The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).	Baseline to Month 24
Number of Participants With Cognitive Impairment for Each New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)	The NY-AACENT is not a validated scale. It was included in this trial because of concerns that regulatory authorities (the European Committee for Medicinal Products for Human Use [CHMP] and the Paediatric Sub-Committee of the European Medicinal Agency [PDCO]) had regarding drug induced cognitive impairment. No validated scale addressing these issues was available at the time of the trial. The NY-AACENT was used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems. It was specifically designed to be used in pediatric populations (ages 12 to 17), but could have been utilized with other age groups, as appropriate.	Baseline to Month 24
Baseline and Post-Baseline Tanner Staging	Tanner staging was completed together with the physical examination by the same trial-affiliated clinician in the most inconspicuous manner for the participant as possible. Tanner staging assessment consisted of 2 domains (pubic hair and breast development) for girls and 3 domains (pubic hair, penis development, and testes development) for boys. A participant who reached Stage 5 (both in pubic hair and genitalia) did not need to continue with Tanner Staging assessment and the Tanner Staging scales of this participant were imputed as 5 for all of the following scheduled time points up to and including the completion visit/ET visit. The clinician arrived at a single score summarizing the domains (not individual domain scores) when evaluating the participant. The total shift data for last visit is presented below.	Baseline to Last Visit
Mean Change From Baseline for Columbia-Suicide Severity Rating Scale (C-SSRS) in Suicidal Ideation Intensity Total Score	Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.	Baseline to Month 24
Incidence of Suicidality, Suicidal Behavior and Suicidal Ideation	Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The below reported N value is the number of participants with specified suicidal ideation/behavior at the given time point.	Baseline to Month 24
Percentage of Participants Who Discontinued Due to All Adverse Events	The percentage of participants who discontinued due to all causes other than sponsor terminating the trial was measured from the date of entering the open-label treatment phase to the date of ET for discontinued participants in the open-label treatment phase (ie, time to discontinuation = date of discontinuation [or date of completion for completed participants] - date of participant entering the open-label treatment phase + 1). If the participants completed the trial or were discontinued due to the sponsor terminating the trial, they were censored at the time of completion or trial termination, respectively.	Baseline to Month 24
Mean Change From Baseline in Positive and Negative Symptoms Score (PANSS) Total Score	The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).	Baseline to Month 24
Mean Change From Baseline in PANSS Positive Subscale Score	The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).	Baseline to Month 24
Mean Change From Baseline in PANSS Negative Subscale Score	The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).	Baseline to Month 24
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score	The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.	Baseline to Month 24
Mean Change in Clinical Global Impression-Improvement (CGI-I) Score	The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.	Baseline to Month 24
Mean Change From Baseline in Young Mania Rating Scale (YMRS) Score	The YMRS consists of 11 items assessing the core symptoms of mania and was used to assess participants with bipolar I disorder, manic and mixed episodes with or without psychotic features: elevated mood, increased motor activity - energy, sexual interest, sleep, irritability, speech (rate and amount), language - thought disorder, content, disruptive - aggressive behavior, appearance, and insight. Each item had 5 or 9 grades of severity, with lower scores indicating milder symptoms. The number of raters within each trial center was to be kept to a minimum. The YMRS Total Score (range 0 to 44) is the sum of the rating scores for 11 items for assessing the core symptoms of mania. A missing value for any YMRS assessment item(s) could have resulted in a missing YMRS Total Score. A higher YMRS Total Score represents greater severity. In this study, 94 participants had bipolar disorder, this explains the N=94 in the table below and these were de novo participants.	Baseline to Month 24
Mean Change From Baseline in Clinical Global Impression Scale - Bipolar (CGI-BP) Version Severity Score	The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Data for 94 de novo participants were available with bipolar disorder.	Baseline to Month 24
Mean Change From Baseline in Clinical Global Impression Scale - Bipolar Version Improvement Score	The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Only 94 participants had data at Baseline to explain the N=94 in the table below and these were de novo participants.	Baseline to Month 24
Mean Change From Baseline in General Behavior Inventory (GBI) Scale Total Score for Mania and Depression in Both Parent/Guardian and Subject Version of the Scale	The GBI is a self-report inventory with 73 items focusing on mood-related behaviors, including depressive, hypomanic, and biphasic symptoms. For this trial, two 20-item subscales were utilized: one was completed by the parent/guardian or legal representative, as applicable for local laws, and the other was completed by the participant. Responses were given on a 4-point Likert scale, with 0 being never or hardly ever and 3 being very often or almost constantly. The GBI Total Score for mania (range 0 to 30) is the sum of scores for items 1 to 10 and the GBI Total Score for depression (range 0 to 30) is the sum of scores for items 11 to 20 in the GBI Parent/Guardian or Subject Version panel. Scores from the Parent/Guardian and participant Versions were summarized separately. A missing value for any GBI assessment items could have resulted in a missing GBI Total Score. High scores represent greater psychopathology. Data was only available for 80 de novo participants with bipolar disorder.	Baseline to Month 24
Mean Change From Baseline in the Attention Deficit Hyperactive Disorders Rating (ADHD-RS-IV) Scale Score	The ADHD-RS-IV is a reliable and easy-to-administer instrument both for diagnosing ADHD in children and adolescents and for assessing treatment response. Containing 18 items, the scale was linked directly to DSM-IV-TR diagnostic criteria for ADHD. There were 3 versions of the scale: a parent questionnaire on home behaviors (English), a parent questionnaire on home behaviors (Spanish), and a teacher questionnaire on classroom behaviors. For this trial, the parent questionnaire on home behaviors (English) was utilized. The ADHD-RS-IV Total Score (range 0 to 54) is the sum of rating scores for 18 items, with higher scores representing greater severity. A missing value for any ADHD-RS-IV assessment items could have resulted in a missing ADHD-RS-IV Total Score. Data were only available for 82 participants with bipolar disorder and these were de novo participants.	Baseline to Month 24
Mean Change From Baseline in Children's Global Assessment Scale (CGAS) in Bipolar (de Novo Participants)	The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6 to 17. It was adapted from the Adults Global Assessment Scale. The Global Assessment Scale was a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS Score (range 1 to 100) is a single-item score for rating a child's general level of functioning on a health-illness continuum, with higher scores representing better functioning.	Baseline to Month 24

Collaborators and Investigators

• Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Investigators: Study Director: Eva Kohegyi, MD, Otsuka Pharmaceutical Development and Commercialization, Inc.

Study record dates

Study Major Dates

• Study Start: July 1, 2010
• Primary Completion (Actual): August 1, 2014
• Study Completion (Actual): September 1, 2014

Study Registration Dates

• First Submitted: May 6, 2010
• First Submitted That Met QC Criteria: May 12, 2010
• First Posted (Estimate): May 13, 2010

Study Record Updates

• Last Update Posted (Estimate): February 8, 2016
• Last Update Submitted That Met QC Criteria: January 8, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Keywords: adolescent; schizophrenia; bipolar
• Additional Relevant MeSH Terms: Schizophrenia Spectrum and Other Psychotic Disorders; Bipolar and Related Disorders; Schizophrenia; Psychotic Disorders; Mental Disorders; Bipolar Disorder; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Antidepressive Agents; Dopamine Agonists; Dopamine Agents; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Dopamine D2 Receptor Antagonists; Dopamine Antagonists; Aripiprazole
• Other Study ID Numbers: 31-09-267